Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "Zydus-Lifesciences"

144 News Found

Zydus Lifesciences acquires rights to market MonoFerric injections in India and Nepal
News | September 10, 2022

Zydus Lifesciences acquires rights to market MonoFerric injections in India and Nepal

MonoFerric, iron isomaltoside 1000 solution for injection/infusion, is a rapid, single dose IV iron developed to reduce the number of infusions


Zydus Lifesciences Q1 FY23 consolidated PAT up at Rs. 518.3 Cr
News | August 11, 2022

Zydus Lifesciences Q1 FY23 consolidated PAT up at Rs. 518.3 Cr

The company has reported total income of Rs. 4138.6 crores during the period ended June 30, 2022.


Briefs: Zydus Lifesciences and Kimia Biosciences
News | August 09, 2022

Briefs: Zydus Lifesciences and Kimia Biosciences

The inspection concluded with four Form 483 observations. None of the observations were related to data integrity.


Zydus Lifesciences receives USFDA approval for Adapalene and Benzoyl Peroxide Topical Gel
Drug Approval | June 07, 2022

Zydus Lifesciences receives USFDA approval for Adapalene and Benzoyl Peroxide Topical Gel

The drug will be manufactured at the group’s topical facility at Ahmedabad


Zydus Lifesciences receives final approval from USFDA for Pemetrexed for Injection
Drug Approval | May 26, 2022

Zydus Lifesciences receives final approval from USFDA for Pemetrexed for Injection

Pemetrexed for Injection has a market size of USD 1,236 mn (as per IQVIA MAT March’22)


Zydus Lifesciences receives final approval from USFDA for Cyanocobalamin Injection
Drug Approval | April 18, 2022

Zydus Lifesciences receives final approval from USFDA for Cyanocobalamin Injection

The drug will be manufactured at the group's injectables manufacturing facility at Jarod, Gujarat


Zydus Lifesciences subsidiary Sentynl acquires BridgeBio’s Nulibry
Biotech | March 09, 2022

Zydus Lifesciences subsidiary Sentynl acquires BridgeBio’s Nulibry

Nulibry is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder


Cadila Healthcare is now Zydus Lifesciences
News | February 24, 2022

Cadila Healthcare is now Zydus Lifesciences

Zydus unveils its ‘innovation and care’ centric corporate brand identity


Zydus receives final approval from USFDA for Tretinoin Cream
Drug Approval | April 28, 2024

Zydus receives final approval from USFDA for Tretinoin Cream

The drug will be manufactured at the group's topical manufacturing facility at Changodar, Ahmedabad (India)


Zydus’ new drug application of Desidustat tablets accepted by China Medical System Holdings
Drug Approval | April 23, 2024

Zydus’ new drug application of Desidustat tablets accepted by China Medical System Holdings

Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients